Key Takeaways
- Johnson & Johnson jumped 4.4% to $269 on October 22, recovering from the 6.9% intraday drop that followed its Q3 MedTech miss.
- MedTech sales rose just 2.5% to $8.6 billion, while Innovative Medicine grew 7.7% to $16.76 billion behind Tremfya and Caplyta.
- VARIPULSE Pro hit 100% acute procedural success in 225 atrial fibrillation patients, but the system still lacks U.S. clearance.
- J&J now leans toward spinning off its hips-and-knees unit after reported $20 billion sale talks with Apollo.
Nine days ago, Johnson & Johnson (JNJ) fell as much as 6.9% and headed for its steepest one-day drop since April 2025. On Thursday, the stock jumped 4.4% to $269, above where it traded before the selloff.
No single headline explains the move. Healthcare stocks have rallied as investors look for safety from tech debt worries, and J&J posted strong real-world data for its VARIPULSE Pro heart ablation system the same day.
Still, the bounce papers over the issue that sank the stock. MedTech grew just 2.5% in Q3, and J&J now has to decide what to do with its hips-and-knees business.
Drugs sprint, devices jog
The quarter split cleanly in two:
- Sales rose 5.9% to $25.4 billion, and adjusted EPS of $2.59 beat the $2.54 estimate
- Innovative Medicine grew 7.7% to $16.76 billion, led by Tremfya up 68% and Caplyta up 66%
- MedTech rose 2.5% to $8.6 billion, short of the $8.71 billion estimate and the second straight miss
GAAP EPS fell to $0.09 after a one-time charge tied mostly to J&J’s proposed talc settlement. Management still nudged 2026 guidance to about $101.2 billion in sales and $11.10 in adjusted EPS at the midpoint.
Mizuho (MFG) analyst Jared Holz called the device weakness “really across the board” in a client note.
Here are the two businesses side by side.
Innovative Medicine now produces about two-thirds of sales, and its lead keeps widening.
A heart bet for MedTech
J&J needs a MedTech growth engine, and electrophysiology is its best candidate.
The new VARIPULSE Pro study covered 225 atrial fibrillation patients at 19 European centers. It posted 100% acute procedural success, a 0.4% primary adverse event rate and a 17.9-minute mean ablation time, with a single catheter used in 88.9% of cases.
Separate 12-month OMNYPULSE data showed 82.5% freedom from documented arrhythmia recurrence. VARIPULSE Pro sells in Europe, Japan and parts of Asia and Latin America, though it still lacks U.S. clearance.
Hospital budgets are getting tighter. Abbott (ABT) just cut its 2026 sales growth forecast, and CFO Joe Wolk said in an interview that Gulf states still want premium systems “but their budgets now are being resourced” toward defense.
How does J&J’s growth stack up against its device rivals?
Boston Scientific (BSX) has set the pace in this group, and J&J’s ablation push has to close that gap.
TIKR tracks 23 analysts on Johnson & Johnson. How many say “Buy”?
See the full breakdown of Buy, Hold, and Sell ratings on Johnson & Johnson, along with Wall Street’s revenue and earnings estimates, all in one place. More than 500,000 investors use TIKR to research stocks like this one. See Johnson & Johnson’s Analyst Ratings
Paying a pharma price
At $269, J&J trades at 23.2x forward earnings, above AbbVie at 18.9x. The average Street target of $279 implies less than 4% upside.
That premium is hard to square with consensus, which expects EPS to grow just 3.8% a year over the next two years. The balance sheet is clean at 0.82x net debt to EBITDA, so investors are paying for safety and the drug pipeline.
Orthopedics is the other open question. Talks to sell DePuy Synthes’ hips-and-knees unit to Apollo Global Management (APO) for about $20 billion surfaced in September, but J&J now leans toward a spinoff.
That premium looks even starker against J&J’s own past…
The multiple sits near the top of its five-year range.
My take: Thursday’s jump looks like sector rotation to me, and it says little about MedTech. I like the electrophysiology data, but a 23x multiple needs devices back above 5% growth, and a clean DePuy separation would help the most.
Q4 results in January should bring 2027 guidance and, ideally, a firm call on orthopedics. That is the moment to judge whether MedTech’s slide has bottomed.
So what is Johnson & Johnson stock actually worth?
TIKR lets you forecast the future price of any stock in less than a minute. Just enter a few assumptions into TIKR’s valuation model and see what Johnson & Johnson could be worth. Start from Wall Street consensus estimates, or adjust the inputs to reflect your own view of the business. It’s free to use.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
